Growth, puberty and endocrine function in beta-thalassaemia major

Journal of Pediatric Endocrinology and Metabolism

Volumn 10, Issue 2, 1997, Pages 175-184

  Low, Louis C K ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; DEFEROXAMINE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; INSULIN; SEX HORMONE; SOMATOMEDIN C;

BETA THALASSEMIA; CHILD GROWTH; CLINICAL TRIAL; ENDOCRINE DISEASE; ENDOCRINE FUNCTION; GONADOTROPIN DEFICIENCY; GROWTH RETARDATION; HUMAN; HYPOPARATHYROIDISM; HYPOTHYROIDISM; INSULIN DEPENDENT DIABETES MELLITUS; INTRAMUSCULAR DRUG ADMINISTRATION; PUBERTY; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THALASSEMIA MAJOR;

EID: 0031006274     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.1997.10.2.175     Document Type: Review

References (59)

1. Kattamis C, Touliatos N, Haidas S, Matsaniotis N. Growth of children with thalassaemia: effect of different transfusion regimens. Arch Dis Child 1970; 45: 502-505.
2. Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, severe, refractory anaemia with hemochromatosis. Circulation 1964; 30: 698-705.
3. Brittenham GM, Griffith PM, Nienhaus AW, McLaren CE, Young NS, Tucker EE, Allan CJ, Farrell DE, Harris JW. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassaemia major. N Engl J Med 1994; 331: 567-573.
4. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994; 331: 574-578.
5. Borgna-Pignatti C, De Stefano, P, Zonta L, Vullo C, De Sanctis V, Melevendi C, Naselli A, Masera G, Terzoli S, Gabutti V, Piga A. Growth and sexual maturation in thalassaemia major. J Pediatr 1985; 106: 150-155.
6. Lucarelli G, Galimberti M, Polchi P, Angelucci E, Baronciani D, Giardini C, Andreani M, Agostinelli F, Albertini F, Clift RA. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993; 329: 840-844.
7. Borgna-Pignatti C, Zurlo MG, DeStefano P, Boffa C, De Sanctis V, Di Palma A, DiGregorio L, Melevendi C, Piga A, Sabato V. Outcome of thalassemia treated with conventional therapy. Bone Marrow Transplant 1993; 12 (Suppl): 2-4.
8. Kattamis C, Liakopoulou T, Kattamis A. Growth and development in children with thalassaemia major. Acta Paediatr Scand 1990; (Suppl) 366: 111-117.
9. Kwan EYW, Lee ACW, Li AMC, Tam CF, Chan CF, Lau YL, Low LCK. A cross-sectional study of growth, puberty and endocrine function in patients with thalassaemia major in Hong Kong. J Paediatr Child Health 1995; 31: 83-87.
10. Yesilpek MA, Bircan I, Oygur N, Ertug H, Yegin O, Guven AG. Growth and sexual maturation in children with thalassemia major. Haematologica 1993; 78: 30-33.
11. De Sanctis V, Katz M, Vullo C, Bagni B, Ughi M, Wonke B. Effect of different treatment regimes on linear growth and final height in β-thalassemia major. Clin Endocrinol 1994; 40: 791-798.
12. De Luca F, Simone E, Corona G, Pandullo E, Siracusano MF, Arrigo T. Adult height in thalassaemia major without hormonal treatment. Eur J Paediatr 1987; 146: 494-496.
13. Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freeman MH, Holland FJ. Effect of age at the start of iron chelation therapy on gonadal function in β-thalassemia major. N Engl J Med 1990; 323: 713-719.
14. Rodda CP, Reid ED, Johnson S, Doery J, Mathews R, Bowden DK. Short stature in homozygous β-thalassemia is due to disproportionate truncal shortening. Clin Endocrinol 1995; 42: 587-592.
15. Low LCK, Kwan E, Cheung PT, Li A, Ha SY, Lau Y, Karlberg J. Growth and puberty in children with β-thalassemia major. 21st International Symposium on Growth Hormone and Growth Factors in Endocrinology and Metabolism. Venice 1996. Abstract 81.
16. Vassilopoulou-Sellin R, Oyedeji CO, Foster PL, Thompson MM, Saman NA. Haemoglobin as a direct inhibitor of cartilage growth in vitro. Horm Metab Res 1989; 21: 11-14.
17. Vannasaeng S, Fucharoen S, Pootrakul P, Ployburr S, Yansukon P. Pituitary function in thalassemic patients and the effect of chelation therapy. Acta Endocrinol 1991; 124: 23-30.
18. Costin G, Kogurt MD, Hyman CB, Ortega JA. Endocrine abnormalities in thalassaemia major. Am J Dis Child 1979; 133: 497-502.
19. Landau H, Gross V, Dagan I, Palti Z, Rachmilewitz EA, Spitz IM. Growth and sexual development before and after sex steroid therapy in patients with thalassaemia major. Arch Intern Med 1984; 144: 2341-2346.
20. Wang C, Tso SC, Todd D. Hypogonadotropic hypogonadism in severe β-thalassemia: effect of chelation and pulsatile gonadotropin-releasing hormone therapy. J Clin Endocrinol Metab 1989; 68: 511-516.
21. Kletzky OA, Costin G, Marrs RP, Bernstein G, March CM, Mishell DR Jr. Gonadotropin insufficiency in thalassaemia major. J Clin Endocrinol Metab 1979; 48: 901-905.
22. Oerter KE, Kamp GA, Munson PJ, Nienhuis AW, Cassorla FG, Manasco PK. Multiple hormone deficiencies in children with hemochromatosis. J Clin Endocrinol Metab 1993; 76: 357-361.
23. Italian Working Group on Endocrine Complications in Non-endocrine Diseases. Multicentre study on prevalence of endocrine complications in thalassaemia major. Clin Endocrinol 1995; 42: 581-586.
24. Chatterjee R, Katz M, Cox TF, Porter JB. Prospective study of the hypothalamic-pituitary axis in thalassaemic patients who developed secondary amenorrhoea. Clin Endocrinol 1993; 39: 287-296.
25. Bergeron C, Kovacs K. Pituitary siderosis. A histologic, immunocytologic and ultrastructural study. Am J Pathol 1978; 93: 295-309.
26. Grundy RG, Woods KA, Savage MO, Evan JPM. Relationship of endocrinopathy to iron chelation status in young patients with thalassaemia major. Arch Dis Child 1994; 71: 128-132.
27. Bozzola M, Argente J, Cisternino M, Moretta A, Valtorta A, Biscaldi I, Donnadieu M, Evain-Brion D, Seven F. Effect of human chorionic gonadotropin on growth velocity and biological growth parameters in adolescents with thalassaemia major. Eur J Paediatr 1989; 148: 300-303.
28. De Virgillis S, Congio M, Frau F, Argiolu F, Diana G, Cucca F, Varsi A, Sanna G, Podda G, Fodde M, Pirastu GF, Cao A. Deferoxamine-induced growth retardation in patients with thalassaemia major. J Pediatr 1988; 113: 661-669.
29. Orzincolo C, Scutellari PN, Castaldi G. Growth plate injury of the long bones in treated β-thalassemia. Skeletal Radiol 1992; 21: 39-44.
30. Olivieri NF, Koren G, Harris J, Khattak S, Freedman MH, Templeton DM, Bailey JD, Reilly BJ. Growth failure and bony changes induced by deferoxamine. Am J Pediatr Haematol/Oncol 1992; 14: 48-56.
31. Prasad AS. Clinical, biochemical and nutritional spectrum of zinc deficiency in human subjects: an update. Nutr Rev 1983; 41: 197-208.
32. Arcasoy A, Cavdar A, Cin S, Erten J, Babacan E, Gozdasoglu S, Akar N. Effects of zinc supplementation on linear growth in beta-thalssaemia (A new approach). Am J Hematol 1987; 24: 127-136
33. Allen TM, Manoli A, Lamont RL. Skeletal changes associated with copper deficiency. Clin Orthop 1982; 168: 206-210.
34. Banford A, Isaac J, Roberts S. The effect of deferoxamine on transferrin receptors, the all cycle and growth rates of human leukaemic cells. Biochem J 1986; 49: 236-243.
35. Olivieri NF, Weatherall DJ. Recent progress in the management of thalassaemia. Hong Kong J Paediatr 1996; 1:1-10.
36. Masala A, Meloni T, Gallisai D, Alagna S, Rovasio PP, Rassu S, Milla AF. Endocrine function in multi-transfused prepubertal patients with homozygous β-thalassemia. J Clin Endocrinol Metab 1984; 58: 667-670.
37. McIntosh N. Endocrinopathy in thalassaemia major. Arch Dis Child 1976; 51: 195-201.
38. Flynn DM, Fairney A, Jackson D, Clayton BE. Hormone changes in thalassaemia major. Arch Dis Child 1976; 51: 828-836.
39. Tolis G, Politis C, Kontopoulou I, Poulatzas N, Rigas G, Saridakis C, Athanasiou V, Mortoglou A, Malachtari S, Ling N. Pituitary somatotropic and corticotropic function in patients with β-thalassemia on iron chelation therapy. Birth Defects 1988; 23: 449-452.
40. Leger J, Girot R, Crosnier H, Poste-Vinay MC, Rappaport R. Normal growth hormone (GH) response to GH-releasing hormone in children with thalassaemia major before puberty: a possible age related effect. J Clin Endorinol Metab 1989; 69: 453-456.
41. Pintor C, Cella SG, Manso P, Corda R, Dessi C, Locatelli V, Muller EE. Impaired growth hormone (GH) response to GH-releasing hormone in thalassemia major. J Clin Endocrinol Metab 1986; 62: 263-267.
42. Leheup BP, Cisternino M, Bozzola M, Donsset B, Mavradi PL, Antoniazzi F, Tato L, Seven F, Sommelet D, Pierson M. Growth hormone response following growth hormone releasing hormone injection in thalassemia major: influence of pubertal development. J Endocrinol Invest 1991; 14: 37-40.
43. Shehadeh N, Hazani A, Rudolf MCJ, Peleg I, Benderly A, Hochberg Z. Neurosecretory dysfunction of growth hormone secretion in thalassaemia major. Acta Paediatr Scand 1990; 79: 790-795.
44. Saenger P, Schwarte E, Markenson AL, Graziano JH, Levine LS, New MI, Hilgartner MW. Depressed serum somatomedin activity in β-thalassemia J Pediatr 1980; 96: 214-218.
45. Werther GA, Mathews RN, Burger HG, Herrington AC. Lack of response of non-suppressible insulin-like activity in thalassaemia major. J Clin Endocrinol Metab 1981; 53: 806-809.
46. Herrington AC, Werther GA, Mathews RN, Burger HG. Studies on the possible mechanism for deficiency of non-suppressible insulin-like activity in thalassaemia major. J Clin Endocrinol Metab 1981; 52: 393-398.
47. Postel-Vinay MC, Girat R, Leger J, Hocquette JF, McKelvie P, Amar-Costesec A, Rappaport R. No evidence for a defect in growth hormone binding to liver membrane in thalassemia major. J Clin Endocrinol Metab 1989; 68: 94-98.
48. Sklar CA, Liu LQ, Yoon DJ, David R. Adrenal function in thalassaemia major following long-term treatment with multiple transfusions and chelation therapy. Evidence for dissociation of cortisol and adrenal androgen secretion. Am J Dis Child 1987; 141: 327-330.
49. Pintor C, Loche S, Faedda A, Puggioni R, Nurchi AM, Fanni V, Corda R. Sexual maturation and adrenal function in girls with thalassaemia. J Endocrinol Invest 1984; 7: 181-184.
50. Landau H, Matoth I, Landau-Cordova Z, Goldfarb A, Rachmilewitz EA, Glaser B. Cross-sectional and longitudinal study of the pituitary-thyroid axis in patients with thalassaemia major. Clin Endocrinol 1993; 38: 55-61.
51. Magro S, Puzzonia P, Consarino C, Galati MC, Morgione S, Porcelli D, Grimaldi S, Tancre D, Arcuri V, De Sanctis V, Alberti A. Hypothyroidism in patients with thalassaemia syndrome. Acta Haematol 1990; 84: 72-76.
52. Delange F, Burgi H. Iodine deficiency disorders in Europe. WHO Bulletin 1989; 67: 317-325.
53. De Sanctis V, Zurlo MG, Senesi E, Boffa C, Cavallo L, Di Gregorio F. Insulin dependent diabetes in thalassaemia. Arch Dis Child 1988; 63: 58-62.
54. Gutteridge JMC, Halliwell B Iron toxicity and oxygen radicals. In: Hershko C, ed, Iron Chelating Therapy. London: Baillierre Tindal 1989; 195-256.
55. Weintraub LR, Goral A, Grasso J, Franzblau C, Sullivan A, Sullivan S. Collagen biosynthesis in iron overload. Ann NY Acad Sci 1988; 526: 179-184.
56. Fujisawa I, Morikawa M, Nakano Y, Konishi J. Hemochromatosis of the pituitary gland: MR imaging. Radiology 1988; 168: 213-214.
57. Scacchi M, Danesi L, De Martin M, Dubini A, Forni L, Masala A, Gallisai D, Burrai C, Terzoli S, Bofla C, Marzano C, Cavagnini F. Treatment with biosynthetic growth hormone of short thalassaemic patients with impaired growth hormone secretion. Clin Endocrinol 1991; 35: 335-339.
58. Low LCK, Kwan EYW, Lim YJ, Lee ACW, Tam CF, Lam KSL. Growth hormone treatment of short Chinese children with β-thalassaemia major without GH deficiency. Clin Endocrinol 1995; 42: 359-363.
59. Kwan EYW, Tam SCF, Karlberg J, Lam KSL, Low LCK. The metabolic effects of growth hormone in children with β-thalassaemia major. Abstract in the 77th Endocrine Society Meeting, Washington, USA 1995; 156.